Navigation Links
Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
Date:9/17/2007

NEW YORK, Sept. 17 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that I. Craig Henderson, MD, the Company's President, will present an overview of the Company's cancer pipeline at the upcoming Bank of America 37th Annual Investment Conference in San Francisco. Dr. Henderson's presentation will take place on Wednesday, September 19th at 8:30 am PT.

Dr. Henderson's presentation will be webcast live and will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of the webcast will be available following the conclusion of the live presentation.

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals, Inc. is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx's lead compound under development is Sulonex(TM) (sulodexide), previously referred to as KRX-101, a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life-threatening kidney disease caused by diabetes. Sulonex is in a pivotal Phase III and Phase IV clinical program under a Special Protocol Assessment with the Food & Drug Administration. Additionally, Keryx is developing Zerenex(TM), an oral, inorganic, iron-based compound that has the capacity to bind phosphate and form non-absorbable complexes. Zerenex is currently in Phase II clinical development for the treatment of hyperphosphatemia (elevated serum phosphorous levels) in patients with end-stage renal disease. Keryx is also developing clinical-stage oncology compounds, including KRX-0401 (perifosine), a novel, first-in-class, oral modulator of Akt, a pathway associated with tumor survival and growth, and other important signal transduction pathways. KRX- 0401 is currently in Phase II clinical development for multiple tumor types. Keryx also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.

KERYX CONTACT:

Lauren Fischer

Director - Investor Relations

Keryx Biopharmaceuticals, Inc.

Tel: 212.531.5965


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2020)... ... March 25, 2020 , ... ... its veterinary histopathology laboratory located centrally in the midwest for high-quality, quick-turn, ... work with a highly motivated, independent, professional team that is focused on ...
(Date:3/12/2020)... ... 12, 2020 , ... With the beginning of 2020, Park ... investment in Europe by inaugurating a new scientific facility for academic and industrial ... Nanoscience Center Europe took place Tuesday, February 18, 2020, gathering customers, collaborators and ...
(Date:3/4/2020)... WASHINGTON (PRWEB) , ... March 04, 2020 , ... This ... Exhibition in Orlando, FL. The company will showcase both expanded and emerging offerings that ... HIMSS 2020 is designed to be comprehensive, timely, and engaging. From ...
(Date:2/26/2020)... , ... February 25, 2020 , ... ... & Biosciences (DuPont) recently published the results of its safety assessment on the ... HMOs currently identified in human milk. These complex carbohydrates are indigestible and therefore ...
Breaking Biology Technology:
(Date:3/13/2020)... HILLSBORO, Oregon (PRWEB) , ... March 13, 2020 ... ... into an agreement with Vivorte Inc. to be the exclusive distributor of the ... its sales, marketing, and medical education expertise to distribute Vivorte’s calcium phosphate-based bone ...
(Date:3/11/2020)... ... March 11, 2020 , ... Polysense Technologies ... smart human body temperature infrared touch-free monitoring product family, a standalone thermal meter ... supporting flexible wireless uplink for cloud connectivity such as NB-IoT, Wi-Fi, LoRaWAN, and ...
(Date:3/9/2020)... ... March 09, 2020 , ... ... 64% last year, as enterprises sought to achieve competitive advantage by transforming ... 13% of all transformation efforts delivered the intended consequences. , Application transformation ...
Breaking Biology News(10 mins):